BHI THERAPEUTIC SCIENCES ABSTRACT TO BE PRESENTED AT GERMAN STEM CELL CONFERENCE
BHI Therapeutic Sciences (BHITS) has been invited to present its abstract, “A retrospective chart review study of allogeneic umbilical cord blood mononuclear cell therapy for stroke,” at the German Stem Cell Network;s 7th Annual GSCN Conference being held Sept. 23-25 at the Max Delbruck Center for Molecular Medicine in Berlin. Marina Manvelyan, PhD., BHITS Clinical Research Scientist said: “We are excited to be part of this gathering to share knowledge with other scientists across the globe. We look forward to learning more about what our colleagues...
Read MoreBHI Therapeutic Sciences Inc. Notified by FDA that is can proceed with New Drug Clinical Trial for Acute Ischemic Stroke
BHI Therapeutic Sciences (BHITS), a leader in stem cell therapy and research utilizing human umbilical cord blood, announced today that the company has been notified by the Food and Drug Administration (FDA) that its Investigational New Drug (IND) application to allow for the initiation of a clinical study of an FDA-approved cell therapy (HCP, cord blood) for treatment of acute ischemic stroke may proceed. Phase 1/2 Study entitled “Evaluation of the Safety and Efficacy of Hemacord HPC, Cord Blood in Subjects with Acute Ischemic Stroke” is a prospective, open-label, single-center,...
Read MoreProfessional Physique Champion is named Ambassador for BHI Slovakia.
Anton Antipov, an International Federation of Body Building and Fitness (IFBB) professional physique champion and fitness model, recently visited BHI Slovakia, stem cell research and treatment center, where he was named an ambassador for the healthcare organization. Mr. Antipov is an accomplished competitor and New York-based model, who has made a name for himself on social media and in the fitness industry. Growing up in Belarus, Mr. Antipov never had access to a gym, but he played sports to stay fit. After his family immigrated to America in the 1990s, Mr. Antipov had his first experience...
Read MoreStem Cells: The Next Frontier documentary screening for investors in NYC.
BHI Therapeutic Sciences (BHITS) and Brian Mehling, M.D. hosted a private screening of Stem Cells: The Next Frontier on Tuesday, February 13 in New York. The evening included a Q & A session and information on how to participate by becoming an investor to make these life-saving stem cells therapies more accessible to patients across the globe. “At BHITS, our philosophy is that stem cells are the future of medicine and we are excited to share our ideas with the general public and investors. BHITS is pioneering ethical, effective, safe and affordable stem cell treatment therapies...
Read MoreBHI Therapeutic Sciences attended the World Economic Forum in Davos, Switzerland.
The 2018 World Economic Forum (WEF) in Davos explored the ideas, innovations and discoveries that are reshaping our world by working closely with those in the vanguard of change from such fields as the arts, culture, engineering, media, medicine, science, and technology. During the past few days, the US-based company BHI Therapeutic Sciences (BHITS) represented by Brian Mehling, MD, Founder and Chief Medical Officer; Klara Doert, President of International Business Development; Katarina Novakova, Director of Relations; and Manuel McDonald, International Consultant attended the annual meeting...
Read MoreWORLD-RENOWNED STEM CELL RESEARCHER AND BOARD-CERTIFIED SURGEON, DR. BRIAN MEHLING, SET TO ATTEND THE 48TH ANNUAL WORLD ECONOMIC FORUM IN DAVOS
FOUNDER OF BLUE HORIZON INTERNATIONAL AVAILABLE TO DISCUSS BREAKTHROUGHS IN STEM CELL RESEARCH ZURICH, Switzerland – January 18, 2017 – Dr. Brian Mehling, world-renowned stem cell researcher, board-certified orthopedic trauma surgeon, and founder of Blue Horizon International (BHI), will be attending The 48th Annual World Economic Forum (WEF) in DAVOS from January 23-26. This will be Dr. Mehling’s sixth year attending the global conference. The theme of this year’s forum is “Creating a Shared Future in a Fractured World” and discussions will centralize around how...
Read More
